A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity.
about
Heterozygous alpha 2A-adrenergic receptor mice unveil unique therapeutic benefits of partial agonists.Progesterone receptor knockout mice have an improved glucose homeostasis secondary to beta -cell proliferationOrphan nuclear receptors in drug discoveryT2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding propertiesStructural and Biochemical Basis for the Binding Selectivity of Peroxisome Proliferator-activated Receptor to PGC-1Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agentRevealing a steroid receptor ligand as a unique PPARγ agonistOn the metabolically active form of metaglidasen: improved synthesis and investigation of its peculiar activity on peroxisome proliferator-activated receptors and skeletal muscles'Striking the Right Balance' in Targeting PPARgamma in the Metabolic Syndrome: Novel Insights from Human Genetic StudiesPPARdelta is a fatty acid sensor that enhances mitochondrial oxidation in insulin-secreting cells and protects against fatty acid-induced dysfunctionAre thiazolidinediones good or bad for the heart?The Concise Guide to PHARMACOLOGY 2013/14: nuclear hormone receptors.PPARgamma regulates adipose triglyceride lipase in adipocytes in vitro and in vivo.MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema.Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR gamma hypomorphic mice.Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1cTranscriptional coregulators: fine-tuning metabolism.Cyclin D3 promotes adipogenesis through activation of peroxisome proliferator-activated receptor gamma.Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harmScreening for bioactive metabolites in plant extracts modulating glucose uptake and fat accumulationSelective cyclo-oxygenase-2 inhibitors impair adipocyte differentiation through inhibition of the clonal expansion phase.Monogenic syndromes of abnormal glucose homeostasis: clinical review and relevance to the understanding of the pathology of insulin resistance and beta cell failure.Homeostatic levels of SRC-2 and SRC-3 promote early human adipogenesis.The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis.Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk.Evolution of peroxisome proliferator-activated receptor agonists.Targeting PPARγ Signaling Cascade for the Prevention and Treatment of Prostate Cancer.Absence of the steroid receptor coactivator-3 induces B-cell lymphoma.Lessons in obesity from transgenic animals.PPARgamma and metabolism: insights from the study of human genetic variants.Modulation of PPARγ provides new insights in a stress induced premature senescence model.Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylationIdentification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis.Antiallergic Function of KR62980, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in a Mouse Allergic Rhinitis Model.Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance.Pharmacological repression of PPARγ promotes osteogenesisPPARgamma as a new therapeutic target in inflammatory bowel diseasesAdipose tissue: new therapeutic targets from molecular and genetic studies--IASO Stock Conference 2003 report.Naturally improving insulin resistance with amorfrutins.Peroxisome proliferator-activated receptor gamma: the more the merrier?
P2860
Q24535863-A6E54004-C2D0-4932-A748-D03AC60FE2C6Q24539994-F79F3671-7681-4903-90A1-0098B668C913Q24649596-E4F4161F-4336-4E3A-854D-A693AC32C25DQ27649827-2F979154-6042-490F-BDE2-BD0E94891D65Q27650576-8077C953-223A-488A-82F6-B63A899DD928Q27653305-6F86ABEA-2D91-4F3C-9B87-4077E0B46FA7Q27674914-E889BB58-A8A8-41A2-A8EC-8C65067ABA4FQ27697692-73062F3F-6A7A-4929-8DB9-B650A789E988Q28221639-0C7C6102-9520-4F29-9393-89C1E132D9BDQ28574319-E3C33AC2-CA96-4E5E-B48F-1C3EEF224549Q30435005-633945C8-690D-4F3B-A657-4BD07E9F5C46Q30486738-E8B4CCD3-2B48-466E-81C2-D2D0EE6A9178Q33641441-7C708EAA-4019-4D11-AA3C-BC7A1E726A09Q33642155-16456979-00EE-4C94-8B66-C79FBC0EA7E9Q33717836-BEA50D8E-0378-4094-A6C2-D5B3B4ABE31CQ33785270-18A95308-884C-40DE-9460-B6FCBF318CDAQ33838571-7B12907A-6764-491E-9917-672CB7B7D53CQ34124151-61BC9544-467F-4406-AE6F-EE6B1DFFB969Q34165847-BA6A8CAB-AAF5-48D2-A2A6-37067665F209Q34183013-DDC853BE-2859-471D-808C-42F18B4CF629Q34210726-A59B5F68-7033-4888-A589-6BE9A49FE184Q34403650-364983DA-4568-468F-A7B7-4E2AE4C9E5FAQ34483124-9956B0CE-3285-477F-A93E-572249DF60E2Q34623928-EDC8E799-58D0-4B60-BC82-A3DD63F482A6Q34628781-1AA42D96-864F-443F-94F8-6872FA8B5D0AQ34630829-C8109C1F-B9FA-49CC-AED2-AA34D4DD9A81Q34646050-F2A05DA8-4B6D-47B9-B6DB-442788262387Q34676664-486E04EF-86A0-4CA3-BD22-D137A45F7234Q35037252-BB553EDE-4113-4205-9C60-4F76D2E5AFB3Q35200033-D796BAAA-ABF2-45D8-A141-B85C3BF2ED0CQ35220970-798AA5E1-F8FA-4136-9F48-923D67B2BF1FQ35230678-93794E52-42E0-4DEB-BE9D-7AB1FA36BC25Q35237706-BAA97C10-6515-418A-8421-D3A24812A293Q35420583-30979DD4-E67F-4B0A-97B9-AAC22E808C8DQ35677716-0E960818-62E5-4DD9-98B0-7697BAD8DE76Q35754510-5195FEB3-014A-4E86-9DFC-707BC171D4C1Q35768913-333C23BB-C405-444B-A5A0-19D45CB96F46Q35905506-DA54D00E-B838-495F-A33E-4167EA83F314Q35983091-2B59D37B-D6E7-4D5A-806C-E9133AE46076Q36018557-7D38DC80-7DBE-4F40-BBA1-B8F6217FE5D2
P2860
A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity.
@en
type
label
A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity.
@en
prefLabel
A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity.
@en
P2093
P1433
P1476
A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity.
@en
P2093
Blanchard SG
Desreumaux P
Leesnitzer LM
Plunket KD
P304
P356
10.1016/S1097-2765(01)00353-7
P577
2001-10-01T00:00:00Z